Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME8BPN)

Drug Name
ALN-APP Drug Info
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DME8BPN

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
APP messenger RNA (APP mRNA) TTG51ON A4_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT05231785) A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD). U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight